Analysts’ Top Healthcare Picks: Definium Therapeutics (DFTX), Lantheus (LNTH)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Definium Therapeutics (DFTX – Research Report), Lantheus (LNTH – Research Report) and Kymera Therapeutics (KYMR – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Definium Therapeutics (DFTX)
In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Definium Therapeutics, with a price target of $32.00. The company’s shares closed last Friday at $17.14.
According to TipRanks.com, Brisebois is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Definium Therapeutics with a $35.30 average price target, which is a 100.3% upside from current levels. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $25.00 price target.
See the top stocks recommended by analysts >>
Lantheus (LNTH)
Truist Financial analyst Richard Newitter maintained a Buy rating on Lantheus today. The company’s shares closed last Friday at $74.02.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lantheus with a $88.50 average price target, representing a 16.9% upside. In a report released yesterday, William Blair also upgraded the stock to Buy with a $106.00 price target.
Kymera Therapeutics (KYMR)
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Kymera Therapeutics today. The company’s shares closed last Friday at $92.65.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kymera Therapeutics with a $119.44 average price target, which is a 31.7% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $103.00 price target.
